Company attributes
Other attributes
Blueprint Genetics is a genomics company headquartered in Helsinki, Finland founded by Juha Koskenvuo, Samuel Myllykangas, Tero-Pekka Alastalo, and Tommi Lehtonenis in 2012. The company offers genetic testing, genetic analysis, and clinical interpretation of genomic data for medical professionals. The company tailors its genomic analysis for medical professionals working within specialty felids of medicine. Medical specialities supported by Blueprint Genetics genomic testing and analysis platform include: Cardiology; Dermatology; Ear, Nose, & Throat; Endocrinology; Gastroenterology; Hematology; Hereditary Cancer; Immunology; Malformations; Metabolic Disorders; Nephrology, Neurology; Ophthalmology; and Pulmonology.
On September 1, 2014 Blueprint Genetics closed a venture funding round with $3.9 million in funding from Inventure.
On December 31, 2016 Blueprint Genetics closed their second venture funding round with €6 million in funding from Pontos Group and Inventure.
On July 11, 2017 Blueprint Genomics closed their series A funding round with €14 million in funding from MTIP AG, Creathor Ventures, Inventure, Pontos Group, and Stanford University.
